Virtual Evaluations of Joint Health Using Wearable Sensors in Persons With Haemophilia (VESPA)

Launched by EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST · Sep 14, 2023

Keywords

ClinConnect Summary

The VESPA trial is studying how wearable sensors can help monitor joint health in people with haemophilia. This technology allows both patients and their healthcare teams to keep track of walking ability and joint function without needing to visit a clinic. The goal is to see if these sensors can provide useful information about how well rehabilitation exercises are working while patients are at home. Early results suggest that after a 12-week exercise program, these sensors can detect improvements, which could help in managing their condition more effectively.

To participate in this trial, individuals need to be over 12 years old and diagnosed with severe or moderate haemophilia. Unfortunately, those with mild haemophilia, certain other bleeding disorders, or specific health issues may not be eligible. Participants can expect to wear the sensors at home and receive real-time feedback on their joint health, which can be shared with their care team. Additionally, the trial will include educational activities to help ensure that the use of this new technology is well integrated into their ongoing treatment and management plans.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of severe or moderate haemophilia (FVIII or FIX ≤ 5%)
• • Aged \> 12 years of age
• • Inhibitor or non-inhibitor, previous or current
• Exclusion Criteria:
• • Diagnosis of mild haemophilia (FVIII or FIX \> 5%)
• • Diagnosis of von Willebrand Disease or other bleeding disorder
• • Aged ≤ 12 years of age
• • Participants requiring a sterile environment
• • The use of an oxygen-rich environment at a participant's home
• • Participants or another person at the participant's home, with sensitive medical equipment whose functions may be compromised by the introduction of the IMU units, such as a pacemaker or implantable defibrillator
• • Bedridden patients
• • Patients with severe cognitive or psychiatric disorders as confirmed by a medical diagnosis